s*e
2 楼
from seeking alpha.
Biogen (NASDAQ:BIIB) Q1 results ($M): Total Revenues: 2,726.8 (+6.7%); Net
Product Sales: 2,309.4 (+6.3%).Net Income: 970.9 (+18.0%); Non-GAAP Net
Income: 1,049.4 (+16.6%); EPS: 4.43 (+26.9%); Non-GAAP EPS: 4.79 (+25.4%).
Key Product Sales: Tecfidera: 945.9 (+7.1%); Total Interferon (Avonex +
Plegridy): 670.4 (-11.1%); Tysabri: 477.0 (+3.1%); Eloctate: 107.7 (+100.9%).
我觉得是相当不错的earning.
Biogen (NASDAQ:BIIB): Q1 EPS of $4.79 beats by $0.32.Revenue of $2.73B (+7.1
% Y/Y) misses by $20M.
2千万 miss 相对27亿的营收算统计误差。
【在 z*********1 的大作中提到】
: No one talk about BIIB er and biotech section?
Biogen (NASDAQ:BIIB) Q1 results ($M): Total Revenues: 2,726.8 (+6.7%); Net
Product Sales: 2,309.4 (+6.3%).Net Income: 970.9 (+18.0%); Non-GAAP Net
Income: 1,049.4 (+16.6%); EPS: 4.43 (+26.9%); Non-GAAP EPS: 4.79 (+25.4%).
Key Product Sales: Tecfidera: 945.9 (+7.1%); Total Interferon (Avonex +
Plegridy): 670.4 (-11.1%); Tysabri: 477.0 (+3.1%); Eloctate: 107.7 (+100.9%).
我觉得是相当不错的earning.
Biogen (NASDAQ:BIIB): Q1 EPS of $4.79 beats by $0.32.Revenue of $2.73B (+7.1
% Y/Y) misses by $20M.
2千万 miss 相对27亿的营收算统计误差。
【在 z*********1 的大作中提到】
: No one talk about BIIB er and biotech section?
相关阅读